Disc Medicine (IRON) Retained Earnings (2020 - 2026)
Disc Medicine (IRON) reported Retained Earnings of -$573.7 million for Q1 2026, down 72.75% year-over-year from -$2.1 billion in Q1 2025, and down 59549.74% on a QoQ basis from $965000.0 in Q4 2025.
Disc Medicine (IRON) has 7 years of Retained Earnings data on file, last reported at -$573.7 million in Q1 2026.
- Quarterly Retained Earnings fell 72.75% year-over-year to -$573.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$573.7 million (down 72.75% YoY) and the FY2025 annual result came in at $965000.0, up 233.91% from the prior year.
- Retained Earnings fell to -$573.7 million in Q1 2026 per IRON's latest filing, from $965000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $965000.0 in Q4 2025 and bottomed at -$573.7 million in Q1 2026.
- The 5-year median for Retained Earnings is -$203.5 million (2022), against an average of -$212.9 million.
- Peak annual rise in Retained Earnings reached 233.91% in 2025, while the deepest fall reached 645400.0% in 2025.
- Tracing IRON's Retained Earnings over 5 years: stood at -$112.2 million in 2022, then tumbled by 47.13% to -$165.1 million in 2023, then soared by 100.18% to $289000.0 in 2024, then jumped by 233.91% to $965000.0 in 2025, then sank by 59549.74% to -$573.7 million in 2026.
- Per Business Quant, the three latest IRON Retained Earnings figures stand at -$573.7 million (Q1 2026), $965000.0 (Q4 2025), and -$449.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - | -573.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -573.69 Mn |
| Dec 31, 2025 | 965,000.00 |
| Sep 30, 2025 | -449.70 Mn |
| Jun 30, 2025 | -387.30 Mn |
| Mar 31, 2025 | -332.09 Mn |
| Dec 31, 2024 | 289,000.00 |
| Sep 30, 2024 | -268.50 Mn |
| Jun 30, 2024 | -60,000.00 |
| Mar 31, 2024 | -215.60 Mn |
| Sep 30, 2023 | -165.10 Mn |
| Jun 30, 2023 | -150.90 Mn |
| Mar 31, 2023 | -135.00 Mn |
| Dec 31, 2022 | -112.22 Mn |
| Sep 30, 2022 | -210.29 Mn |
| Jun 30, 2022 | -207.01 Mn |
| Mar 31, 2022 | -199.92 Mn |
| Dec 31, 2021 | -65.39 Mn |
| Sep 30, 2021 | -166.87 Mn |
| Jun 30, 2021 | -148.32 Mn |
| Mar 31, 2021 | -131.87 Mn |
| Dec 31, 2020 | -112.82 Mn |
| Sep 30, 2020 | -500,911.00 |